(Q34577661)

3 August 2017

title

No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

3 August 2017

0 references

0 references

6

Gavin Giovannoni

1 reference

3 August 2017

5

Gary Cutter

0 references

Richard M. Nixon

series ordinal

1

object named as

Richard Nixon

1 reference

3 August 2017

Niklas Bergvall

2

1 reference

3 August 2017

Davorka Tomic

series ordinal

3

1 reference

3 August 2017

Nikolaos Sfikas

series ordinal

4

1 reference

3 August 2017

language of work or name

English

0 references

publication date

21 November 2014

1 reference

3 August 2017

1 reference

3 August 2017

volume

31

1 reference

3 August 2017

issue

11

1 reference

3 August 2017

page(s)

1134-1154

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-014-0167-z

3 August 2017

exact match

0 references

cites work

Meta-analysis of a binary outcome using individual participant data and aggregate data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

Current disease-modifying treatment of multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

No head-to-head trial? simulate the missing arms.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

Freedom from disease activity in multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

Meta-analysis of continuous outcomes combining individual patient data and aggregate data

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

How should meta-regression analyses be undertaken and interpreted?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

7 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0167-Z

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0167-Z

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0167-Z

Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0167-Z

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0167-Z

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0167-Z

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4245493

Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool

27 October 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0167-Z

Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0167-Z

Network meta-analysis for indirect treatment comparisons

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25414048

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25414048

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12325-014-0167-Z

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference